At a virtual event for investors on Thursday, modern scientists and staff plan to fight a new strain of the virus as the cause of the Covid-19, with new waves of the epidemic coming.
The virus is changing rapidly as it spreads, said Melissa Moore, the agency’s chief scientific officer. Some of these new viral strains seem to be more contagious than the original strains … We already know that these few new strains are less susceptible to being neutralized by our current vaccine.
The company says it is testing new variants in the lab against its vaccines and is constantly creating and testing new versions of its vaccines. He warned, however, that the process was not immediate and that the agency’s activities were limited by the complexity of the work.
Guillaume Stout-Jones, a modern scientist who has worked as an associate director of design and selection of antigens in your infectious disease, says the shortest time to start reading the preclinical immunogenicity against a pseudovirus panel is about 2 to 3 months. Team. And new viral forms are coming, constantly evolving in real time.
The company combined its messenger RNA engineering and messenger RNA particles in the presentation that provided a summary of its various scientific programs in a variety of ways, including discussions about the efficacy of lipid nanoparticles.
However, analysts’ questions at the end of the call focused almost entirely on their Covid-19 vaccines. In a note released on Thursday, SVB Lynch analyst Mani Forohr wrote that the vaccine is another indication of how important the vaccine is to Modena’s current stock valuation.
In a separate note, Jefferies analyst Michael Yeh wrote that the presentation demonstrated Modern’s leadership in messenger RNA-based therapy.
They are investing in machine engineering to ensure that they build individual mRNAs … and it will be a key breed for anyone who can create mRNAs, writes Yeh.
Shares of Modarna rose 2.3% on Thursday and fell 0.4% on Friday.
The Barons argued in an article in late April that there was room for modern stock to grow and that there was concern about the market value of Wall Street, which at the time was $67 billion and now $70.5 billion.
Foroohar and Yee are more cautious. Foroohar has an underperforming rating on Moderna, at a price target of $ 83, while Yee has a retention rating and a price target of $ 170. Moderna closed at $179.54 on Thursday and is up 71.9% so far this year and more than 220% in the last 12 months.